Synergistic Antitumor Effect of Bispecific CD19 X CD3 and CD19 X CD16 Diabodies in a Preclinical Model of Non-Hodgkin's Lymphoma

Journal of Immunology - United States
doi 10.4049/jimmunol.169.1.137
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The American Association of Immunologists

Related search

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma

American Journal of Hematology
Hematology
2019English

Cd19

2017English

Efficient Elimination of Chronic Lymphocytic Leukaemia B Cells by Autologous T Cells With a Bispecific Anti-Cd19/Anti-Cd3 Single-Chain Antibody Construct

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2003English

Molecular Analysis of a CD19-negative Diffuse Large B-Cell Lymphoma

Haematologica
Hematology
2018English

The Novel Bispecific Cd47-Cd19 Antibody Tg-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Table 2: Correlation of MAIT Cell Populations (% CD3+CD19− T-Cells) With WOMAC Scores.

English

Selection of a Novel CD19 Aptamer for Targeted Delivery of Doxorubicin to Lymphoma Cells

Oncotarget
Oncology
2018English

Phase I Study of Anti-Cd3 X Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Prostate Cancer
Cancer ResearchOncologyUrology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy